Comparative Efficacy of Combined and Standalone Oral Immunotherapies for Peanut Allergy: a Bayesian Network Meta-Analysis of RCTs Authors: Xinyu Tian, Shuang Liu, Lisha Li, Kai Guan Published: 2025 ABSTRACT AbstractBackgroundPeanut allergy is a chronic IgE-mediated disease with potentially life-threatening consequences. While several immunotherapeutic strategies have emerged, including oral immunotherapy (OIT), omalizumab (OMA)-based therapies, and probiotic and peanut oral immunotherapy (PPOIT), the comparative effectiveness of these interventions remains unclear. This study aimed to evaluate the relative efficacy and safety of combined and standalone oral immunotherapies for peanut allergy using a Bayesian network meta-analysis (NMA).MethodsA systematic literature search was conducted in PubMed, EMBASE, and Web of Science up to March 2025. We included randomized controlled trials (RCTs) involving patients with IgE-mediated peanut allergy who received OIT + OMA, OMA monotherapy, OIT alone, or PPOIT. Outcomes included low-dose and high-dose desensitization, sustained unresponsiveness (SU), and safety outcomes (adverse events, AEs). The risk of bias was assessed using RoB 2. Analyses were performed using R software (version 4.4.3) with Bayesian NMA methods.ResultsNineteen RCTs involving 2040 participants were included. Based on Probability Scores (P-scores), OIT + OMA demonstrated the highest efficacy for both low- (P-score: 97.20%) and high-dose desensitization (96.69%), followed by PPOIT (70.15% and 51.16%), OIT third (64.40% and 52.72%), and OMA fourth (75.29% and 71.21%). PPOIT and OIT showed moderate efficacy for SU. OIT was associated with a higher frequency of AEs compared with placebo.ConclusionsCombination and modified immunotherapies may offer improved efficacy and safety profiles, though results should be interpreted in the context of limited data and study heterogeneity.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12016-025-09118-2.Keywords: Peanut allergy, Omalizumab, Oral immunotherapy, Probiotic, Network meta-analysis, Desensitization Introduction Food allergy (FA) is a potentially life-threatening chronic disease that has been increasingly prevalent worldwide, with estimates ranging from 0.2% to over 10% across different populations [1]. Peanut allergy (PA), one of the most common immunoglobulin E (IgE)-mediated food allergies, typically develops in early childhood and often persists into adulthood [2]. In most countries, the current management of PA primarily relies on strict avoidance of peanut exposure and prompt treatment of accidental ingestion. Even minor unintended exposure can trigger allergic reactions ranging from mild symptoms such as itching and urticaria to severe, potentially fatal anaphylaxis, which requires immediate epinephrine autoinjection [3]. To address these concerns, allergen immunotherapy (AIT) has emerged as a promising disease-modifying approach. Among these, AR101 (Palforzia™, Aimmune Therapeutics), an oral immunotherapy (OIT), was approved by the U.S. Food and Drug Administration (FDA) for use in children aged 4 to 17 years with PA in 2020 [4, 5]. However, OIT treatment is limited by a high incidence of adverse events (AEs), which were reported in 50–95% of patients during OIT, especially in those with very severe allergies and/or long duration of build-up phase [6]. Therefore, researchers continue to explore alternative or adjunctive treatment strategies for FA. Omalizumab (OMA), a monoclonal anti-IgE antibody, has shown potential both as monotherapy and as an adjuvant to OIT (OMA + OIT) in reducing allergic reactions in patients with IgE-mediated FA [7]. Additionally, probiotic and peanut oral immunotherapy (PPOIT), which combines OIT with specific probiotic strains (Lactobacillus rhamnosus), has demonstrated promising efficacy and safety profiles in peanut-allergic patients [8]. For patients with PA and their clinicians, multiple therapeutic options are available. However, direct comparisons between these interventions remain limited due to the lack of head-to-head randomized controlled trials (RCTs). To address this gap, we conducted a Bayesian network meta-analysis (NMA) of RCTs to evaluate the comparative effectiveness of OMA + OIT, OMA, OIT, and PPOIT, aiming to provide references for clinical practice and future research. Methods Search Strategy A systematic literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [9] to identify RCTs. We searched the following databases from inception to March 2025: PubMed, EMBASE, and Web of Science. The search strategy combined disease-related terms, including controlled vocabulary (e.g., MeSH headings) and relevant free-text keywords (See Tables S1–S3 under Supplementary Document for the full search strategies). This protocol is registered in the International Prospective Register of Systematic Reviews (PROSPERO; number CRD420251052496). Eligibility Criteria The study population included human participants across all age groups—children, adolescents, and adults—with IgE-mediated PA. We included studies that investigated the following interventions: OMA + OIT, OMA monotherapy, OIT, and PPOIT. The comparators of interest were placebo or standard allergen avoidance strategies. Placebo and allergen avoidance were modeled as distinct comparator nodes to avoid mixing blinded and unblinded control conditions. Only RCTs in phase II or higher were eligible. Regarding outcomes, we focused on clinically relevant endpoints rather than laboratory-based measures. The outcomes assessed were efficacy (desensitization and sustained unresponsiveness (SU)) and safety (AEs, incidence of eosinophilic esophagitis (EoE), as well as epinephrine use). Reports of other anti-IgE agents (excluding OMA), single-arm studies, retrospective studies, and conference abstracts were excluded from the analysis. Data Extraction Data were extracted by one author (X.T.) and checked by another (S.L.). Disagreements were resolved through discussion with two additional authors (K.G. and L.L.). From each eligible study, we collected the following information: first author, publication year, country, population characteristics, total sample size, sample size per treatment arm, and outcome assessment methods. In addition, we extracted allergy-related outcomes and their corresponding effect estimates from the main text, figures, tables, and supporting information. For analysis, both effectiveness and safety endpoints were standardized and expressed as binary data (e.g., number of events and total participants). Risk of Bias Assessment We used the modified Cochrane Risk Bias Tool (RoB 2) to evaluate the quality of included studies [10]. This tool evaluates five key domains: (1) risk of bias arising from the randomization process, (2) bias due to deviations from the intended interventions, (3) bias resulting from missing outcome data, (4) bias in the measurement of the outcome, and (5) bias in the selection of the reported results. Publication bias was evaluated through Egger’s test and visual inspection of funnel plots. The overall methodological quality of each trial was evaluated by the reviewers through consensus. Data Statistical Analysis Efficacy outcomes included low-dose desensitization (defined as ingestion of a cumulative dose of at least 250 mg peanut protein with no more than mild symptoms), high-dose desensitization (defined as ingestion of a cumulative dose of at least 4000 mg peanut protein with no more than mild symptoms), and SU (a lack of clinical reaction to a food allergen after active therapy has been discontinued for a period of time [11], during which time participants continued a peanut elimination diet [12]). It should be noted that the duration of SU lacks consensus and may not reflect long-term remission. Safety outcomes encompassed any adverse events (AEs), treatment-related AEs, severe AEs (as defined by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E2A guideline [13] and US Code of Federal Regulations (CFR) 21 Part 312.32 [14]), the number of patients consuming epinephrine, and the number of patients diagnosed with EoE. A Bayesian NMA was conducted using R software (version 4.4.3) with the following packages: ‘rjags’, ‘gemtc’, ‘meta’, ‘netmeta’, ‘ggplot2’, ‘dplyr’. Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated for binary outcomes. Probability Scores (P-scores) were used to rank the relative effectiveness and safety of each intervention. Heterogeneity across studies was assessed using the I2 statistic. A random-effects model was applied for all efficacy and safety endpoints due to substantial heterogeneity. If a study reported no events in one or both treatment arms, the network meta-analytical method in R applied a continuity correction of 0.5 or 1 [15] (‘rjags’ does not accept a non-integer number of events) to studies with zero cell counts to prevent computational errors. P values less than 0.05 are considered statistically significant. Results were presented according to outcome type and treatment comparison. Subgroup analyses were run. Results The Baseline Characteristics A total of 2,327 records were initially identified through database searches. After screening titles and abstracts, 69 full-text articles were assessed for eligibility. Ultimately, 19 studies [5, 8, 16–32] met our criteria (Fig. 1). Among these, OMA was used as monotherapy in two studies [18, 32] and as an adjunct to OIT in another two studies [26, 28]. Two additional articles evaluated PPOIT [8, 29], while the remaining 13 studies [5, 16, 17, 19–25, 27, 30, 31] investigated conventional OIT. The characteristics of the included trials are summarized in Table S4. Based on the mechanism of action, studies using AR101/Palforzia™ (an FDA-approved OIT product) [4] and those using peanut food directly to perform OIT were grouped together for analysis. PRISMA flow diagram [33]: Literature search and screening Risk of Bias RoB 2 was used to evaluate the quality of the included studies. Egger’s test and funnel plot analysis were conducted to evaluate potential publication bias. Detailed risk of bias assessments for each study are presented in the supplementary document (Fig S1). Overall, the methodological quality of the included studies was acceptable. Specifically, studies employing avoidance strategies showed some concerns regarding bias in Domain 2 (deviations from intended interventions), as participants in the control group were necessarily aware of the avoidance diet. The study by Sampson et al. [32] was stopped early based on the recommendation of the Data Safety Monitoring Committee, while the study by Varshney, P. [31] had a small sample size (n = 19 in the OIT group, n = 9 in the control group) and a high withdrawal rate (21% in the OIT group). Both studies exhibited a comparatively higher risk of bias. A subgroup analysis excluding trials with high risk of bias is presented in "Subgroup Analysis of Low-Risk-of-Bias Studies" section. Funnel plots showed no obvious asymmetry for outcomes with sufficient studies (Fig S2), and Egger’s tests were non-significant (P > 0.05). However, Egger’s tests could not be assessed for SU and some safety outcomes (treatment-related AEs and severe AEs) due to insufficient study numbers. Inconsistency Assessment To assess model convergence, trace plots were visually inspected for each outcome to determine whether the Markov chains had stabilized and mixed well [34]. Chains displaying good mixing without apparent trends or patterns across iterations were considered to indicate adequate convergence. Additionally, to evaluate the inconsistency between direct and indirect evidence in the NMA, we performed node-splitting analyses for each pairwise comparison [35]. No statistically significant inconsistencies were observed (p > 0.05, see Table S5 for details), suggesting that the assumption of consistency was reasonable and that direct and indirect evidence agreed. These findings support the validity of the NMA results. It should be noted that no comparisons were available to assess inconsistency for the outcomes of all AEs, epinephrine use, and incidence of EoE. Because the loop in their networks was entirely formed by a multi-arm trail, which cannot be inconsistent, and hence, no comparisons should be split [35]. However, we conducted sensitivity analyses excluding multi-arm trials, and the relative treatment effects remained consistent, suggesting robustness of the findings. Efficacy Only studies that utilized an oral food challenge (OFC) to evaluate desensitization and SU— either open or blinded (single- or double-blind placebo-controlled food challenge, DBPCFC) — were included in the analysis. The league table (Fig. 3) presents all pairwise comparisons of treatment effects, including odds ratios (ORs) and 95% CIs. Forest plots (Fig S3) in the supplementary figures visually summarize these comparisons, with either placebo or allergen avoidance as the reference group. League tables of the network meta-analysis. (A) ORs (95% CI) for Low-dose desensitization. (B) ORs (95% CI) for High-dose desensitization. (C) ORs (95% CI) for SU. (D) ORs (95% CI) for Safety assessed according to AEs of any grade. (E) ORs (95% CI) for Safety assessed according to treatment-related AEs. (F) ORs (95% CI) for Safety assessed according to severe AEs. (G) ORs (95% CI) for the number of patients consuming epinephrine. (H) ORs (95% CI) for the number of patients diagnosed with EoE. OIT: oral immunotherapy, OMA: omalizumab, PPOIT: probiotic and peanut oral immunotherapy, SU: sustained unresponsiveness, AEs: adverse events, EoE: eosinophilic esophagitis Low-Dose Desensitization Low-dose desensitization was defined as the ingestion of a cumulative dose of at least 250 mg peanut protein (approximately 240 mg peanut protein equals 1 whole peanut kernel [36]) with no more than mild symptoms. We compared the proportion of participants achieving this endpoint across treatment groups. The analysis of low-dose desensitization included 19 studies covering 6 interventions (Table S6). A network plot (Fig. 2A) illustrates the comparisons between these treatments, with line thickness representing the number of studies contributing to each direct comparison. Comparative network plots. (A) Low-dose desensitization. (B) High-dose desensitization. (C) SU. (D) Safety assessed according to AEs of any grade. (E) Safety assessed according to treatment-related AEs. (F) Safety assessed according to severe AEs. (G) The number of patients consuming epinephrine (H) The number of patients diagnosed with EoE. Each circle represents a treatment. The line thickness represents the number of studies contributing to each direct comparison. OIT: oral immunotherapy, OMA: omalizumab, PPOIT: probiotic and peanut oral immunotherapy, SU: sustained unresponsiveness, AEs: adverse events, EoE: eosinophilic esophagitis This NMA primarily focused on comparisons against placebo or allergen avoidance strategies; full results were provided in the Appendix (Table S6). Compared with placebo or allergen avoidance, all active treatments — OIT + OMA, OMA, OIT, and PPOIT — significantly increased the proportion of participants achieving low-dose desensitization (Fig. 3A and Fig S3A). Ranking analysis based on P-scores indicates that OIT + OMA had the highest probability of being ranked first (97.19%) for low-dose desensitization. PPOIT was most likely to rank second (70.15%), OIT third (64.40%), and OMA fourth (75.29%) (Fig. 4A, Table S9A). The Bayesian ranking results based on Probability scores. The line graph shows the probability of ranking from first to last for each treatment. The abscissa represents “Rank” and the ordinate represents “Probability”. Different interventions are distinguished by different colored lines. The ranking probability for each intervention corresponds to the position of the circle on the ordinate. (A) Low-dose desensitization. (B) High-dose desensitization. (C) SU. (D) Safety assessed according to AEs of any grade. (E) Safety assessed according to treatment-related AEs. (F) Safety assessed according to severe AEs. (G) Safety assessed according to the number of patients consuming epinephrine. (H) Safety assessed according to the number of patients diagnosed with EoE. OIT: oral immunotherapy, OMA: omalizumab, PPOIT: probiotic and peanut oral immunotherapy, SU: sustained unresponsiveness, AEs: adverse events, EoE: eosinophilic esophagitis High-Dose Desensitization High-dose desensitization was defined as the ingestion of a cumulative dose of at least 4000 mg peanut protein with no more than mild symptoms. We compared the proportion of participants achieving this outcome across treatment groups. The analysis of high-dose desensitization included 12 studies covering 6 interventions (Table S7). A network plot is shown in Fig. 2B. Compared with placebo, OIT + OMA, OIT, OMA, and PPOIT significantly increased the likelihood of achieving high-dose desensitization. However, when compared to avoidance, the significant effect of OMA was no longer observed (Fig. 3B, Fig. S3B). Ranking analysis indicates that OIT + OMA had the highest probability of being ranked first (96.69%) for high-dose desensitization. PPOIT was most likely to rank second (51.16%), OIT third (52.72%), and OMA fourth (71.21%) (Fig. 4B, Table S9B). SU SU was defined as a lack of clinical reaction to a food allergen after active therapy has been discontinued for a period of time [11], during which time participants continued a peanut elimination diet [12]. We compared the proportion of participants achieving this outcome across treatment groups. The analysis included 5 studies covering 4 interventions (Table S8). A network plot is shown in Fig. 2C. Compared with placebo, both OIT and PPOIT were associated with a significantly higher likelihood of achieving SU. However, no significant differences were observed when these interventions were compared with avoidance (Fig. 3C and Fig S3C). Ranking analysis indicates that PPOIT had the highest probability of being ranked first (60.20%) for SU, with OIT most likely to rank second (59.8%) (Fig. 4C, Table S9C). Safety Safety was evaluated based on five outcomes: AEs of any grade, treatment-related AEs, severe AEs, epinephrine use, and EoE. The analysis of any-grade AEs included 11 studies covering 5 interventions (Fig. 2D), while treatment-related AEs were assessed in 4 studies involving 3 interventions (Fig. 2E). Severe AEs were analyzed across 7 studies with 4 interventions (Fig. 2F), epinephrine use was evaluated in 9 studies encompassing 5 interventions (Fig. 2G), and incidence of EoE was evaluated in 9 studies encompassing 5 interventions (Fig. 2H). Compared with placebo, OIT was associated with a significantly higher risk of any grade AEs (OR = 4.46, 95% CI: 1.91–10.17). However, no significant differences were observed in the incidence of treatment-related AEs, severe AEs, use of epinephrine, or incidence of EoE across all treatment comparisons, suggesting that the observed AEs were mostly mild and not associated with serious harm. Bayesian ranking results based on P-scores for safety outcomes are presented in Fig. 4D-H. Subgroup Analysis Heterogeneity existed in the duration of allergen avoidance (2-4 weeks to > 3 months) for SU and maintenance dose of OIT (300–4000 mg protein daily) across studies. However, due to sparse and dispersed data, subgroup analyses were not feasible. Other meaningful subgroup analyses are as follows. Subgroup Analysis in Children Aged 1–5 Years Most evidence on PA comes from studies conducted in children aged 4–17 years or across mixed age groups. However, four studies focused specifically on younger children: Loke, P. [8] reported subgroup results for participants aged 1–5 years, Jones, S. M. [21] and Du Toit, G. [19] included participants aged 1–4 years, and Uhl, C. [17] enrolled children aged 1–3 years. In this subgroup analysis, both PPOIT and OIT significantly increased the likelihood of achieving low-dose desensitization compared with either placebo or allergen avoidance (Fig S4B). Based on P-score rankings, PPOIT had a higher probability of being the most effective intervention (62.72%) than OIT (58.00%) (Fig S4C). For high-dose desensitization, both PPOIT and OIT also showed significant benefits over placebo (Fig S5B), with PPOIT ranked higher than OIT in P-score analysis (Fig S5C). However, the evidence for PPOIT is primarily derived from a single trial, and the difference in ranking probabilities is modest. No studies of OMA monotherapy have been used in children 1–5 years old, and SU analysis was not feasible due to limited data (only two trials). Subgroup Analysis of Low-Risk-of-Bias Studies The studies with a high risk of bias [16, 17, 20, 27, 30–32] according to the RoB 2 tool were excluded from this subgroup NMA. Compared with placebo, all active treatments — OIT + OMA, OMA, OIT, and PPOIT — significantly improved the proportion of participants achieving low-dose desensitization. Among these, OIT + OMA showed the highest probability of effectiveness (97.35%) (Fig S6). Similar results were observed for high-dose desensitization, without data on OMA monotherapy (Fig S7). For SU outcome, both OIT and PPOIT demonstrated significant benefits over placebo (Fig S8B), with OIT ranked slightly higher (OIT: 57.40%, PPOIT: 42.60%) (Fig S8C). Subgroup Analysis of the Duration of OIT There was notable variation in the duration of OIT across studies. The average duration in PPOIT and OIT-only studies was 14.77 months, with some extending up to 39 months [23]. In contrast, the OIT phase in OIT + OMA studies [26, 28] was typically less than 7 months. A subgroup analysis was conducted based on OIT duration (≤ 9 months or > 9 months), with results presented in Fig S9–S11. This analysis provided several insights: First, in studies with shorter OIT durations, OMA ranked higher than OIT in achieving low-dose desensitization (Fig S9C), although the difference was not statistically significant. Additionally, for peanut OIT, longer treatment durations were associated with better outcomes. The OR for achieving low-dose desensitization compared to placebo increased from 15.58 (95% CI: 7.59–34.84) in short-duration studies (Fig S9B) to 38.77 (95% CI: 25.95- 60.07) in long-duration studies (Fig S10B). Third, in the long-duration subgroup, OMA monotherapy lost its significant advantage over placebo for high-dose desensitization observed in the main analysis (Fig S11B); other results were consistent with the primary findings. Subgroup analysis for SU was not performed because all included SU studies had long-duration protocols, and short-duration trials provided insufficient data (only two studies) for high-dose desensitization. Overall, the effectiveness of active interventions remained stable across subgroups defined by OIT duration, with consistent trends observed in both categories. Subgroup Analysis of Trials Using DBPCFC for Outcome Assessment To address heterogeneity in challenge methods (Tables S4), a subgroup analysis restricted to studies using DBPCFC was conducted (Fig S12). The results were consistent with the main analysis. Discussions This NMA included 19 RCTs and aimed to evaluate the comparative efficacy and safety of four interventions — OIT + OMA, OMA, OIT, and PPOIT — in patients with IgE-mediated PA. Our results indicate the following: (1) OIT + OMA was associated with the highest efficacy for both low- and high-dose desensitization. (2) PPOIT exhibited strong efficacy in both desensitization outcomes, ranking close to OIT + OMA. It also showed moderate effectiveness in SU. (3) OIT improved two desensitization outcomes, with a more modest effect on SU. (4) OMA monotherapy showed limited efficacy: no significant effect of high-dose desensitization was observed when compared to avoidance. But it outperformed OIT in studies with treatment duration ≤ 9 months. (5) In terms of safety, all interventions were relatively safe, though OIT alone was linked to more frequent AEs. The mechanisms underlying these findings align with our current understanding of immunological responses to FA. OMA is a monoclonal anti-IgE antibody that binds to free IgE, preventing its attachment to FcεRI receptors on mast cells and basophils, thereby inhibiting allergic degranulation [37, 38]. Although some studies suggest additional immunomodulatory effects, such as promotion of regulatory T cells (Tregs) and Immunoglobulin G4 (IgG4) synthesis [39, 40], OMA has shown only limited efficacy in promoting high-dose desensitization and SU. In contrast, OIT modulates multiple components of the immune response. It induces immune tolerance through repeated oral exposure to allergens, which enhances the function of allergen-specific Tregs that mediate active unresponsiveness [41]. OIT also suppresses basophil and mast cell reactivity, reduces T helper 2 (TH2) cell activity, and drives B cell class-switching [42–44]. These broad immunologic changes support both short-term desensitization and potential long-term tolerance, including SU [43, 44]. Notably, during the initial weeks to months of OIT, there is a rapid increase in specific IgE (sIgE) [45, 46], clinically associated with the high risk of AEs. The addition of OMA can block free IgE and suppress FcεRI activation, reducing reactions and enabling rapid escalation. PPOIT did not show significantly greater efficacy than OIT alone in our network meta-analysis. This is consistent with the original RCT, which reported improved safety but no efficacy benefit with probiotic addition [8]. However, P-score rankings indicated that PPOIT tended to perform better than OIT but slightly worse than OIT + OMA. This trend is likely attributable to the higher maintenance doses and faster dose escalation in OIT protocols with the addition of probiotics [8, 29], both of which are associated with improved desensitization and SU. While some studies suggest probiotics may have potential in food allergy management, human trial evidence remains insufficient to confirm a direct therapeutic effect [47–49]. Thus, the main driver of efficacy remains the OIT component, with probiotics acting as a supportive adjunct. Probiotics may offer a lower-cost adjunctive option to OIT, potentially serving as an alternative to OMA in certain clinical or economic contexts [50]. To the best of our knowledge, this is the first NMA to comprehensively evaluate the efficacy and safety of both combined and standalone oral immunotherapies—including OMA monotherapy—in the management of PA. A previous meta-analysis by Torsten Zuberbier et al. [51] evaluated the efficacy and safety of OMA or OMA + OIT in patients with IgE–mediated food allergy. It showed that OMA + OIT significantly increased desensitization in patients allergic to peanuts (n = 37; single study [28]) versus placebo + OIT. However, for PA specifically, no direct comparison between OMA and placebo was available due to the lack of relevant studies. Similarly, the meta-analysis by Carmen Riggioni et al. [52] focused on immunotherapy and biologics for IgE-mediated food allergy. They reported that, for PA, OIT had a relative risk (RR) of 11.94 (95% CI: 1.76–80.84) compared with avoidance or placebo. For any food allergy, OMA showed a RR of 2.17 (95% CI: 1.22–3.85). Most AEs reported were mild. However, this analysis did not specifically assess OMA monotherapy or OIT + OMA in patients with PA. Another study by Ying-Ying Zhang and Min Zhang et al. [53] evaluated the combination of OMA with AIT versus immunotherapy alone for allergic diseases, including FA. The results indicated that OMA + AIT significantly improved the proportion of patients achieving the target maintenance dose compared with AIT alone. But PA was not analyzed as a separate subgroup. Network meta-analysis offers several advantages over conventional pairwise meta-analysis. It allows for the simultaneous comparison of multiple interventions through both direct and indirect evidence, thereby increasing statistical power and enabling more comprehensive treatment rankings. OIT + OMA was numerically superior in efficacy and had the highest probability of being optimal based on P-scores, though 95% CIs were wide. Rankings should be viewed as exploratory. OMA monotherapy was the least effective strategy compared with other interventions in the analysis. While PPOIT has not yet been widely adopted for PA, it warrants further investigation. When using OIT alone, patients and caregivers should pay attention to AEs, even though most of them are mild to moderate. Overall, this analysis provides valuable insights into the comparative effectiveness of available immunotherapies and may help guide clinical decision-making in the management of PA. Our NMA also has several limitations that should be acknowledged. First, it is important to interpret the estimated ORs with caution. Some ORs — especially for OIT + OMA versus placebo or allergen avoidance (Fig. 3) — were extremely large. This was likely due to the very few or no responders in the control arms and the fact that these estimates were based on only two studies involving a limited number of participants. While this suggests a strong clinical benefit of OIT + OMA, the exact magnitude of the effect may be overestimated. Second, two multi-arm studies [20, 23] were incorporated into the analysis by extracting data from multiple arms to align with the network structure, which may have introduced additional heterogeneity. Third, the majority of included studies were conducted in the United States or Europe, with limited data from other regions such as Asia. Potential differences in genetic background, environmental exposures, or clinical management across populations may limit the generalizability of our findings to other ethnic groups. Fourth, variability in OIT regimens, including escalation speed, maintenance dose, and treatment duration, is known to affect both desensitization and SU outcomes. However, due to limited trial data, these variables could not be explored in the current analysis. Future research should investigate how variations in OIT protocol influence long-term efficacy. Furthermore, the lack of consistent reporting on peanut component sensitization (e.g., Ara h 2) across studies limited our ability to assess how different sensitization patterns—such as primary allergy to storage proteins versus cross-reactivity to panallergens—may influence treatment response. Conclusions This network meta-analysis suggests that OIT + OMA may offer greater efficacy in achieving desensitization compared to OIT or OMA alone. PPOIT and OIT also appeared to improve desensitization, with moderate effects on SU; PPOIT ranked higher than OIT. Notably, there is currently no evidence that OMA—either as monotherapy or in combination with OIT—induces SU, but the low-maintenance OIT doses used in OIT + OMA protocols may limit the potential for achieving SU. In contrast, PPOIT demonstrated efficacy comparable to OIT + OMA in desensitization, suggesting that the addition of a probiotic may offer a cost-effective alternative to OMA without compromising safety or efficacy. OIT was associated with more frequent adverse events, while all interventions were generally well tolerated. The findings indicate potential advantages of combination or modified protocols, but the observed differences should be interpreted in the context of the limited number of studies and heterogeneous study designs. Further high-quality trials are needed to confirm these comparative effects and assess long-term outcomes. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 6716 KB) Acknowledgements This work was supported by the National Natural Science Foundation of China under Grant [82370041] and Peking Union Medical College Hospital Talent Cultivation Program (Category D) [UHB12554]. Author Contribution X.T. was primarily responsible for drafting the manuscript. S.L., L.L., and K.G. contributed to the critical revision and provided intellectual guidance throughout the writing process. All authors read and approved the final version of the manuscript. Data Availability No datasets were generated or analysed during the current study. Declarations Ethical Approval Ethical approval was not required for this study, as it is a network meta-analysis based on previously published data. Conflict of Interest The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary file1 (DOCX 6716 KB) Data Availability Statement No datasets were generated or analysed during the current study.